About UTILITY therapeutics
UTILITY therapeutics is a company based in Altrincham (United Kingdom) founded in 2017 by Peter Villadsen and Rasmus Kehler was acquired by Alembic Pharmaceuticals in July 2025. UTILITY therapeutics has raised $2.52 million across 3 funding rounds from investors including Alembic Pharmaceuticals and AMR Action Fund. The company has 7 employees. UTILITY therapeutics offers products and services including Antibiotic Therapies and Product Pipeline. UTILITY therapeutics operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Altrincham, United Kingdom
- Employees 7
- Founders Peter Villadsen, Rasmus Kehler
- SectorsHealthcare
- Email••••••••
- Website utilitytherapeutics.com
- Social LinkedIn
- Acquired by Alembic Pharmaceuticals (Jul 2025)
- Legal Name Utility Therapeutics Ltd
- Date of Incorporation 19 Dec, 2017
- Jurisdiction ALTRINCHAM, CHESHIRE, UNITED KINGDOM
- Total Equity Funding$2.52M (USD)
in 3 rounds
- InvestorsAlembic Pharmaceuticals
& 1 more
- Employee Count7
- Acquired byAlembic Pharmaceuticals
(Jul 2025)
Products & Services of UTILITY therapeutics
UTILITY therapeutics offers a comprehensive portfolio of products and services, including Antibiotic Therapies and Product Pipeline.
Develops drugs to combat drug-resistant urinary tract infections
Advances novel treatments for UTIs and related infections
Funding Insights of UTILITY therapeutics
UTILITY therapeutics has successfully raised a total of $2.52M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.52M
- Total Rounds 3
- First Round $23,900
(Feb 2018)
- Investors Count 1
All 3 funding rounds of UTILITY therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | – | Debt – Conventional | – | – | |
| Jul 2019 | $2.5M | Seed | – | – | – |
| Feb 2018 | $23,900 | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in UTILITY therapeutics
UTILITY therapeutics has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Alembic Pharmaceuticals and AMR Action Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | amractionfund.com | - | |
Manufacturer & supplier of generic pharmaceuticals | 1907 | alembicpharmaceuticals.com | Vadodara, India |
Investor details for UTILITY therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of UTILITY therapeutics
14 people are tracked at UTILITY therapeutics (8 in leadership, 5 in board & advisors, 1 in team); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Alan Sloane Roemer | Chairman | Leadership |
Thomas Hadley | CEO | Leadership |
Peter Villadsen | Co-Founder | Leadership |
Rasmus Kehler | Co-Founder | Leadership |
Tom Hadley | President & CCO | Leadership |
Anita Das | Head of Biostatistics | Leadership |
Nina Aabenhus Kromann | Acting Head of CMC | Leadership |
Claus Maxel Henriksen | Acting Head of Project Management | Leadership |
Rasmus Toft - Kehler | Co-Founder & Director | Board & advisors |
Morten Sommer | Co-Founder & Director | Board & advisors |
Larry Edwards | Director | Board & advisors |
Anders Kronborg | Observer | Board & advisors |
John Krayacich | Business Advisor | Board & advisors |
Anne Santerre Henriksen | Acting EVP of Development | Team |
Complete people profiles for UTILITY therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of UTILITY therapeutics
4 dated milestones of UTILITY therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded UTILITY therapeutics is founded.
- Funding First funding round of $24K.
- Funding Latest funding round, Debt – Conventional,.
- Exit Acquired by Alembic Pharmaceuticals.
Competitors of UTILITY therapeutics
UTILITY therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| nabriva.com | 2006 | Vienna, Austria | $193.08M | – | Pleuromutilin antibiotics are developed for MDR infections. | |
| melinta.com | 2000 | Morristown, United States | $186M | 290 | Developer of bacterial ribosome-targeting drugs for MDR infections | |
| iterumtx.com | 2015 | Dublin, Ireland | $78.1M | – | Developer of antibiotics for MDR infections | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. | |
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. | |
| locus-bio.com | 2015 | Raleigh, United States | $67.33M | 74 | Developer of therapeutics for infectious disease and inflammatory indications | |
| vedantabio.com | 2010 | Cambridge, United States | $350.49M | 71 | Therapeutics for infectious and autoimmune diseases are developed. | |
| allecra.com | 2013 | – | $44.44M | – | Antibiotics for multi-drug-resistant bacterial infections are developed. | |
| cubist.com | 1993 | Lexington, United States | – | 895 | Pharmaceuticals for acute care bacterial infections are developed and commercialized. |
Detailed competitors of UTILITY therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Utility Therapeutics
Complete news archive for UTILITY therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to UTILITY therapeutics
10 companies that operate in the same segment as UTILITY therapeutics (Genitourinary Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Miniaturized injectable neuromodulation devices are developed for chronic diseases. | 2014 | Santa Clara, California, United States | USD 123.59 M | – | – | |
Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer | 2018 | Maple Grove, Minnesota, United States | USD 157 M | – | 29 | |
A device is developed to treat urinary obstruction from BPH. | 2014 | Palo Alto, California, United States | USD 48 M | – | 25 | |
Minimally invasive devices in urology | 2004 | Mountain View, California, United States | USD 137.96 M | – | 119 | |
Diagnostic devices for lower urinary tract diseases are developed. | 2021 | Aliso Viejo, California, United States | USD 94.99 M | – | 23 | |
Medical device for benign prostatic hyperplasia treatment is developed. | 2021 | Milwaukee, Wisconsin, United States | USD 54.16 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about UTILITY therapeutics
UTILITY therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
UTILITY therapeutics is headquartered in Altrincham, United Kingdom. It is registered at Altrincham, Greater Manchester, United Kingdom.
Thomas Hadley is the current CEO of UTILITY therapeutics.
UTILITY therapeutics is a funded company, having raised a total of $2.52M across 3 funding rounds to date. The company's 1st funding round was a Seed of $23.9K, raised on Feb 2018.
UTILITY therapeutics has 7 employees.
Developer of antibiotics to treat urinary tract infections and multi-drug resistant infections. It offers Pivmecillinam is an aminopenicillin, which is a specific class of beta-lactam antibiotic and mecillinam (a member of the penicillin subgroup of the β-lactam antibiotic class), is an oral prodrug pivmecillinam for the treatment of urinary tract infections.
UTILITY therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
UTILITY therapeutics offers Antibiotic Therapies and Product Pipeline.
UTILITY therapeutics has 2 investors. Key investors include Alembic Pharmaceuticals, and AMR Action Fund.
UTILITY therapeutics operates through Utility Therapeutics Ltd.
Yes. UTILITY therapeutics was acquired by Alembic Pharmaceuticals in July 2025.